CDKN2A and non-small cell lung carcinoma: Monteverde et al. found that CDKN2A could promote nonsmall cell lung cancer (NSCLC) progression by regulating transcriptional elongation, and targeting CDKN2A could enhance therapeutic response in patients with NSCLC [28].